Publications by authors named "Nigel Austin"

Claim this Profile
P
Preclinical pharmacokinetics, metabolism, and disposition of NXE0041178, a novel orally bioavailable agonist of the GPR52 receptor with potential for treatment of schizophrenia and related psychiatric disorders.
Simon Poulter, Nigel Austin, Stephen P Watson, Sarah J Bucknell, M Alistair O'Brien

Xenobiotica· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Identification of GPR52 Agonist HTL0041178, a Potential Therapy for Schizophrenia and Related Psychiatric Disorders.
Simon Poulter, Nigel Austin, Rachel Armstrong, Matt Barnes, Sarah Joanne Bucknell

ACS Med Chem Lett· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of OICR12694: A Novel, Potent, Selective, and Orally Bioavailable BCL6 BTB Inhibitor.
Ahmed Mamai, Anh M Chau, Brian J Wilson, Iain D Watson, Babu B Joseph, Nigel Austin

ACS Med Chem Lett· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Brain-Penetrant and Bioavailable Pyrazolopiperazine BACE1 Inhibitor Elicits Sustained Reduction of Amyloid β In Vivo.
Aldo Peschiulli, Daniel Oehlrich, Michiel Van Gool, Nigel Austin, Sven Van Brandt

ACS Med Chem Lett· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JNJ-67569762, A 2-Aminotetrahydropyridine-Based Selective BACE1 Inhibitor Targeting the S3 Pocket: From Discovery to Clinical Candidate.
Frederik J R Rombouts, Ken-Ichi Kusakabe, Richard Alexander, Nigel Austin, Herman Borghys

J Med Chem· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and optimization of a series of small-molecule allosteric inhibitors of MALT1 protease.
Tianbao Lu, Peter J Connolly, Ulrike Philippar, Weimei Sun, Maxwell D Cummings, Nigel Austin

Bioorg Med Chem Lett· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trifluoromethyl Dihydrothiazine-Based β-Secretase (BACE1) Inhibitors with Robust Central β-Amyloid Reduction and Minimal Covalent Binding Burden.
Kosuke Anan, Yasuyoshi Iso, Takuya Oguma, Kenji Nakahara, Shinji Suzuki, Nigel Austin

ChemMedChem· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice.
Renzo Mancuso, Gemma Fryatt, Madeleine Cleal, Juliane Obst, Elena Pipi, Nigel Austin

Brain· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of an Extremely Potent Thiazine-Based β-Secretase Inhibitor with Reduced Cardiovascular and Liver Toxicity at a Low Projected Human Dose.
Genta Tadano, Kazuo Komano, Shuhei Yoshida, Shinji Suzuki, Kenji Nakahara, Nigel Austin

J Med Chem· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a Series of β-Secretase 1 Inhibitors Containing Novel Heteroaryl-Fused-Piperazine Amidine Warheads.
Daniel Oehlrich, Aldo Peschiulli, Gary Tresadern, Michiel Van Gool, Juan Antonio Vega, Nigel Austin

ACS Med Chem Lett· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of a novel series of cyanoindole derivatives as potent γ-secretase modulators.
François P Bischoff, Adriana Ingrid Velter, Garrett Minne, Serge Pieters, Didier Berthelot, Nigel Austin

Bioorg Med Chem Lett· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to Optimization of 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate.
Harrie J M Gijsen, Sergio A Alonso de Diego, Michel De Cleyn, Aránzazu García-Molina, Gregor J Macdonald, Nigel Austin

J Med Chem· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate.
Harrie J M Gijsen, Sergio A Alonso de Diego, Michel De Cleyn, Aránzazu García-Molina, Gregor J Macdonald, Nigel Austin

J Med Chem· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of DNA barcoding to identify rare endemic vascular plant species in Trinidad.
Fazeeda N Hosein, Nigel Austin, Shobha Maharaj, Winston Johnson, Luke Rostant

Ecol Evol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of N-(Pyridin-4-yl)-1,5-naphthyridin-2-amines as Potential Tau Pathology PET Tracers for Alzheimer's Disease.
Frederik J R Rombouts, José-Ignacio Andrés, Manuela Ariza, José Manuel Alonso, Nigel Austin

J Med Chem· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example.
Frederik J R Rombouts, Fulgencio Tovar, Nigel Austin, Gary Tresadern, Andrés A Trabanco

J Med Chem· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads.
Frederik J R Rombouts, Gary Tresadern, Oscar Delgado, Carolina Martínez-Lamenca, Michiel Van Gool, Nigel Austin

J Med Chem· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Half-life extension of the HIV-fusion inhibitor peptide TRI-1144 using a novel linker technology.
Eric L Schneider, Gary W Ashley, Lieve Dillen, Bart Stoops, Nigel E Austin

Eur J Pharm Biopharm· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application.
Bart Kesteleyn, Katie Amssoms, Wim Schepens, Geerwin Hache, Wim Verschueren, Nigel Austin

Bioorg Med Chem Lett· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators.
Simon E Ward, Mark Harries, Laura Aldegheri, Nigel E Austin, Stuart Ballantine

J Med Chem· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potentiation of the anticonvulsant efficacy of sodium channel inhibitors by an NK1-receptor antagonist in the rat.
Mikhail Kalinichev, Andrea Bradford, Silvia Bison, Adam Lucas, Ilaria Sartori, Nigel E Austin

Epilepsia· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat.
Charles H Large, Mikhail Kalinichev, Adam Lucas, Corrado Carignani, Andrea Bradford, Nigel E Austin

Epilepsy Res· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague-Dawley rats: a locomotor activity and gene induction study.
Mikhail Kalinichev, Melanie J Robbins, Elizabeth M Hartfield, Peter R Maycox, Susan H Moore, Nigel E Austin

Prog Neuropsychopharmacol Biol Psychiatry· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
8
8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.
Tom D Heightman, Laramie M Gaster, Sarah L Pardoe, Jean-Pierre Pilleux, Michael S Hadley, Nigel E Austin

Bioorg Med Chem Lett· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist.
Gregor J Macdonald, Clive L Branch, Michael S Hadley, Christopher N Johnson, David J Nash, Nigel E Austin

J Med Chem· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis